Novel and bone-targeted agents for CRPC

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Fizazi, K ^a   Albiges, L ^a   Massard, C ^a   Escudier, B ^a   Loriot, Y ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Bone targeted agents; Chemotherapy; Endocrine therapy; Immunotherapy; Prostate cancer

Indexed keywords

ABIRATERONE; CABAZITAXEL; CABOZANTINIB; CUSTIRSEN; DASATINIB; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IPILIMUMAB; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISONE; RADIUM CHLORIDE RA 223; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TASQUINIMOD; ZOLEDRONIC ACID;

ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERTENSION; LIFE EXPECTANCY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE;

EID: 84866754578     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds353     Document Type: Article

References (20)

1. Loriot Y, Massard C, Fizazi K. Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. Ann Oncol 2012; 23: 1085-1094.
2. De Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
3. De Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
4. Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of COU-AA-301 phase III study. Submitted.
5. ™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Eur J Cancer 2011; 47(Supp 2); 3.
6. Scher HI, Fizazi K, Saad F et al. Effect of MDV 3100, an androgen receptor signalling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol 2012; 30 (suppl 5). (LBA 1).
7. Loriot Y, Massard C, Gross-Goupil M et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010; 46: 1770-1772.
8. Nilsson S, Franzen L, Parker C et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebocontrolled phase II study. Lancet Oncol 2007; 8: 587-594.
9. Fizazi K, Yang J, Peleg S et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 2003; 9: 2587-2597.
10. Rajpar S, Massard C, Laplanche A et al. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann Oncol 2010; 21: 1864-1869.
11. Fizazi K, Lipton A, Mariette X et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-1571.
12. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
13. Smith DC, Smith MR, Small EJ et al. Phase 2 study of cabozantinib (XL 184) in a cohort of patients with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. J Clin Oncol 2012; 30 (suppl; abstr 4513).
14. Yu EY, Massard C, Gross ME et al. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 2011; 77: 1166-1171.
15. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
16. Slovin SF, Beer TM, Higano CS et al. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2009; 27(suppl 5): 15s. (Abstr 5138).
17. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099-1105.
18. Chi KN, Hotte SJ, Yu EY et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castrationresistant prostate cancer. J Clin Oncol 2010; 28: 4247-4254.
19. Pili R, Häggman M, Stadler WM et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011; 29: 4022-4028.
20. Wirth M, Heidenreich A, Gschwend JE et al. Final analysis: a multicenter phase I study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody to human αv integrins, in progressive castrate-resistant prostate cancer with bone metastases after chemotherapy. J Clin Oncol 2012; 30(Suppl 5). (Abstr 231).